Novel Fabrication of Anti-VEGF Drug Ranibizumab Loaded PLGA/PLA Co-polymeric Nanomicelles for Long-acting Intraocular Delivery in the Treatment of Age-related Macular Degeneration Therapy

Overview

Journal Regen Ther

Date 2024 Sep 16

PMID 39281109

Authors

Jin-Feng Xu

Yan-Ping Wang

Xiao-Hua Liu

Affiliations

Soon will be listed here.

Abstract

Age associated macular degeneration is the 3rd primary cause of blind fundus diseases globally. A reliable and long-lasting method of intraocular drug delivery is still needed. Herein, this study was aim to develop the novel fabrication of ranibizumab loaded co-polymeric nanomicelles (Rabz-CP-NMs) for AMD. The CMC of co-polymeric nanomicelles was determined to be low, at 6.2 μg/ml. The ring copolymerization method was employed to fabricate the NMs and characterize via FTIR, XRD, TEM, DLS and Zeta potential. Rabz-CP-NMs was spherical shape with 10-50 nm in size. Stable and prolonged drug release was achieved with the Rabz from CP-NMs at 48 h. D407 and ARPE19 ocular cell lines showed dose-dependent cell viability with Rabz-CP-NMs. The Rabz-CP-NMs also had less toxicity, higher uptake, lower cell death and prolonged VEGF-A inhibition, as shown by cytoviability assay. Thus, Rabz-CP-NMs were safe for ocular use, suggesting that could be used to improve intraocular AMD treatment.

References

Rosenfeld P, Brown D, Heier J, Boyer D, Kaiser P, Chung C . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. DOI: 10.1056/NEJMoa054481. View

Ashwanikumar N, Kumar N, Nair S, Kumar G . Dual drug delivery of 5-fluorouracil (5-FU) and methotrexate (MTX) through random copolymeric nanomicelles of PLGA and polyethylenimine demonstrating enhanced cell uptake and cytotoxicity. Colloids Surf B Biointerfaces. 2014; 122:520-528. DOI: 10.1016/j.colsurfb.2014.07.024. View

Wang Y, Liu C, Ji T, Mehta M, Wang W, Marino E . Intravenous treatment of choroidal neovascularization by photo-targeted nanoparticles. Nat Commun. 2019; 10(1):804. PMC: 6379485. DOI: 10.1038/s41467-019-08690-4. View

Mandal A, Gote V, Pal D, Ogundele A, Mitra A . Ocular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa®) for Dry Eye Disease. Pharm Res. 2019; 36(2):36. DOI: 10.1007/s11095-018-2556-5. View

Bourges J, Gautier S, Delie F, Bejjani R, Jeanny J, Gurny R . Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci. 2003; 44(8):3562-9. DOI: 10.1167/iovs.02-1068. View

Kim H, Csaky K . Nanoparticle-integrin antagonist C16Y peptide treatment of choroidal neovascularization in rats. J Control Release. 2009; 142(2):286-93. DOI: 10.1016/j.jconrel.2009.10.031. View

Cai R, Zhang L, Chi H . Recent development of polymer nanomicelles in the treatment of eye diseases. Front Bioeng Biotechnol. 2023; 11:1246974. PMC: 10436511. DOI: 10.3389/fbioe.2023.1246974. View

Jiang G, Han X, Qiao K, Liu S . Therapeutic effect of intravitreal anti-VEGF drugs on retinal neovascularization in diabetic retinopathy. Minerva Med. 2022; 115(2):218-220. DOI: 10.23736/S0026-4806.22.07943-5. View

Alshamrani M, Sikder S, Coulibaly F, Mandal A, Pal D, Mitra A . Self-Assembling Topical Nanomicellar Formulation to Improve Curcumin Absorption Across Ocular Tissues. AAPS PharmSciTech. 2019; 20(7):254. DOI: 10.1208/s12249-019-1404-1. View

10.

Dedania V, Bakri S . Current perspectives on ranibizumab. Clin Ophthalmol. 2015; 9:533-42. PMC: 4376306. DOI: 10.2147/OPTH.S80049. View

11.

Kumari A, Yadav S, Yadav S . Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2009; 75(1):1-18. DOI: 10.1016/j.colsurfb.2009.09.001. View

12.

Nagarwal R, Kumar R, Dhanawat M, Pandit J . Modified PLA nano in situ gel: a potential ophthalmic drug delivery system. Colloids Surf B Biointerfaces. 2011; 86(1):28-34. DOI: 10.1016/j.colsurfb.2011.03.023. View

13.

Brown D, Campochiaro P, Singh R, Li Z, Gray S, Saroj N . Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117(6):1124-1133.e1. DOI: 10.1016/j.ophtha.2010.02.022. View

14.

Lu P, Liang Z, Zhang Z, Yang J, Song F, Zhou T . Novel nanomicelle butenafine formulation for ocular drug delivery against fungal keratitis: In Vitro and In Vivo study. Eur J Pharm Sci. 2023; 192:106629. DOI: 10.1016/j.ejps.2023.106629. View

15.

Varshochian R, Riazi-Esfahani M, Jeddi-Tehrani M, Mahmoudi A, Aghazadeh S, Mahbod M . Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment. J Biomed Mater Res A. 2015; 103(10):3148-56. DOI: 10.1002/jbm.a.35446. View

16.

Li Z, Liu M, Ke L, Wang L, Wu C, Li C . Flexible polymeric nanosized micelles for ophthalmic drug delivery: research progress in the last three years. Nanoscale Adv. 2022; 3(18):5240-5254. PMC: 9417891. DOI: 10.1039/d1na00596k. View

17.

Caldorera-Moore M, Liechty W, Peppas N . Responsive theranostic systems: integration of diagnostic imaging agents and responsive controlled release drug delivery carriers. Acc Chem Res. 2011; 44(10):1061-70. PMC: 3219056. DOI: 10.1021/ar2001777. View

18.

Zhang L, Si T, Fischer A, Letson A, Yuan S, Roberts C . Coaxial Electrospray of Ranibizumab-Loaded Microparticles for Sustained Release of Anti-VEGF Therapies. PLoS One. 2015; 10(8):e0135608. PMC: 4537102. DOI: 10.1371/journal.pone.0135608. View

19.

Sousa F, Cruz A, Fonte P, Mendes Pinto I, Neves-Petersen M, Sarmento B . A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles. Sci Rep. 2017; 7(1):3736. PMC: 5473878. DOI: 10.1038/s41598-017-03959-4. View

20.

Oremusova J, Vitkova Z, Vitko A, Tarnik M, Miklovicova E, Ivankova O . Effect of Molecular Composition of Head Group and Temperature on Micellar Properties of Ionic Surfactants with C12 Alkyl Chain. Molecules. 2019; 24(3). PMC: 6384972. DOI: 10.3390/molecules24030651. View